|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Transcutaneous perianal sonography:A sensitive method for the detection of perianal inflammatory lesions in Crohn's disease显示文摘AIM: Pelvic magnetic resonance imaging (MRI) and endoanalultrasound which are established imaging methods forperianal inflammatory lesions in patients with Crohn'sdisease require expensive specialized equipments andexpertise. We investigated the feasibility and sensitivity oftranscutaneous perianal ultrasound (PAUS) using regularultrasound probes in the imaging of perianal inflammatorylesions. The sonographic findings were correlated to pelvicMRI-scans.METHODS: We performed PAUS in 25 patients with Crohn'sdisease and clinical signs of perianal inflammatory disease.VCChin a median of 10 d (range 0-75) these patients underwentMRI of the pelvis. Regular convex and linear high resolutionprobes were used for PAUS. The sonographic findings werecorrelated to the MRI findings by blinded investigators.RESULTS: The sonographic investigations were welltolerated by all patients. Fistulae typically presented ashypoechoic tracks. Twenty-nine fistulae were detected in22 patients. Abscesses were detected in 7 patients andpresented as hypo- or anechoic formations. Twenty-six of29 fistulae and 6 of 7 abscesses could be confirmed byMRI. Kappa statistics showed an excellent agreement(kappa>0.83) between the two imaging methods.CONCLUSION: PAUS is a simple, painless, feasible, real-time method that can be performed without specific patientpreparation which is comparable in its sensitivity to pelvicMRI in the detection of perianal fistulae and/or abscesses.PAUS can especially be recommended as a screening toolin acute perianal disorders such as perianal abscess andfor follow-up studies of perianal inflammatory disease. | Jochen Wedemeyer Timm Kirchhoff Gernot Sellge Oliver Bachmann Joachim Lotz Michael Galanski Michael P.Manns Michael J.Gebel Jrg S.Bleck | 2004 | World Journal of Gastroenterology2004，10，19： | 8 |
| 2 | Initial experience from a combination of systemic and regional chemotherapy in the treatment of patients with nonresectable cholangiocellular carcinoma in the liver显示文摘AIM: In nonresectable cholangiocellular carcinoma (CCC)therapeutic options are limited. Recently, systemic chemotherapy has shown response rates of up to 30%.Additional regional therapy of the arterially hyper vascularized hepatic tumors might represent a rational approach in an attempt to further improve response and palliation. Hence, a protocol combining transarterial chemoembolization and systemic chemotherapy was applied in patients with CCC limited to the liver.METHODS: Eight patients (6 women, 2 men, mean age 62 years) with nonresectable CCC received systemic chemotherapy (gemcitabine 1 000 mg/m2) and additional transarterial chemoembolization procedures (50 mg/m2cisplatin, 50 mg/m2 doxorubicin, up to 600 mg degradable starch microspheres). Clinical follow-up of patients, tumor markers, CT and ultrasound were performed to evaluate maximum response and toxicity.RESULTS: Both systemic and regional therapies were tolerated well; no severe toxicity (WHO Ⅲ/Ⅳ) was encountered. Nausea and fever were the most commonly observed side effects. A progressive rarefication of the intrahepatic arteries limited the maximum number of chemoembolization procedures in 4 patients. A median of 2 chemoembolization cycles (range, 1-3) and a median of 6.5 gemcitabine cycles (range, 4-11) were administered.Complete responses were not achieved. As maximum response, partial responses were achieved in 3 cases,stable diseases in 5 cases. Two patients died from progressive disease after 9 and 10 mo. Six patients are still alive. The current median survival is 12 mo (range, 9-18); the median time to tumor progression is 7 mo (range, 3-18). Seven patients suffered from tumor-related symptoms prior to therapy, 3 of these experienced a treatment-related clinical relief. In one patient the tumor became resectable under therapy and was successfully removed after 10 mo.CONCLUSION: The present results indicate that a combination of systemic gemcitabine therapy and repeated regional chemoembolizations is well tolerated and may enhance the effect of palliation in a selected group of patients with intrahepatic nonresectable CCC. | Timm Kirchhoff Lars Zender Sonja Merkesdal Bernd Frericks Nisar Malek Joerg Bleck Stefan Kubicka Stefan Baus Ajay Chavan Michael P.Manns Michael Galanski | 2005 | World Journal of Gastroenterology2005，11，8： | 3 |
| 3 | Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience显示文摘 | H. L.Tillmann J.Hadem L.Leifeld K.Zachou A.Canbay C.Eisenbach I.Graziadei J.Encke H.Schmidt W.Vogel A.Schneider U.Spengler G.Gerken G. N.Dalekos H.Wedemeyer M. P.Manns | 2006 | Journal of Viral Hepatitis2006，，4： | 1 |
| 4 | Lamivudine therapy in chronic delta hepatitis: a multicentre randomized‐controlled pilot study显示文摘 | G. A.NIRO A.CIANCIO H. L.TILLMAN M.LAGGET A.OLIVERO F.PERRI R.FONTANA N.LITTLE F.CAMPBELL A.SMEDILE M. P.MANNS A.ANDRIULLI M.RIZZETTO | 2005 | Alimentary Pharmacology & Therapeutics2005，，3： | 1 |
| 5 | 自身免疫性肝炎的分类和自身抗体对发病机制及诊断的意义显示文摘自身免疫性肝炎是一原因不明症状群,病毒、细菌、化学物质和药物是遗传敏感个体诱发自身-参与炎症性疾病过程的潜在病因。自身免疫性肝炎的诊断根据许多临床和实验室指标,自身抗体是重要的诊断指标,常规实验室的检测方法是间接免疫荧光法。然而,间接免疫荧光法并不能区分个别抗体抗原系统,过去数年应用分子生物学技术。 | Michaels P.Manns 郝连杰 | 1999 | 德国医学1999，16，3： | 1 |
| 6 | Prevalence of adverse reactions to food in patients with gastrointestinal disease显示文摘 | S. C.Bischoff A.Herrmann M. P.Manns | 2008 | Allergy2008，，11： | 1 |
| 7 | 肝细胞癌的免疫治疗(上)显示文摘肝细胞癌(HCC)是世界第五大常见肿瘤,5年生存率低于5%,每年至少100万新发病例。其中一小部分病人可能适合外科切除或者局部消融治疗。但是,这些治疗受到肿瘤大小、肝脏储备功能和肝内转移的限制。因此,对于绝大多数晚期HCC患者来说,这些有望治愈的治疗手段都是不可能的。肝动脉化疗栓塞术(TACE)延长了已无条件行外科手术切除、肝移植或肿瘤消融治疗的患者的生存期,但是只有那些肝功能适当的患者才能够进行此项治疗。因为HCC患者基本上都有肝硬化基础,全身化疗耐受性较差,并且效果不佳。因此,根据全球性的指南(EASL或AASLD),像免疫治疗一类的备选方案最近正在晚期HCC患者中进行评估。 | Tim F.Greten Michael P.Manns Firouzeh Korangy 姚勤伟(编译) 杨月(审校) | 2007 | 传染病网络动态2007，，1： | 0 |
| 8 | 肝细胞癌的免疫治疗(下)显示文摘5.肿瘤逃逸机制
肿瘤从免疫系统产生了很多逃逸机制来抑制抗肿瘤反应。产生免疫抑制因子、增加调节性T细胞、下调肿瘤抗原和MHC分子都是肿瘤细胞用以逃避免疫识别的机制。已有很清楚的证据显示发生HCC能导致肿瘤特异性免疫反应受到抑制。尤其是我们已经证实尽管在超过50%的HCC患者中检测到肿瘤特异性的细胞和体液免疫反应,但是HCC仍然有所进展。虽然有抗原特异性T细胞的出现但HCC肿瘤仍然进展,这增加了对免疫治疗该肿瘤的有效性的关注。因为下面会展示,HCC的发展导致一系列不同的免疫机制,结果就是HCC患者中肿瘤特异性免疫反应的抑制。 | Tim F.Greten Michael P.Manns Firouzeh Korangy 姚勤伟(编译) 杨月(审校) | 2007 | 传染病网络动态2007，，2： | 0 |
| 9 | 丙型肝炎:许多老病的新病毒显示文摘自从1989年确定丙型肝炎病毒之后,关于丙型肝炎病毒分子结构和生物学的识识已有了其显著的提高。最令人激动的领域是 HCV 与免疫系统的相互作用,HCV 感染引起组织损伤的机理,特别是病毒本身的致细胞病变的程度如何?细胞对病毒惑染的免疫反应可致何种程度肝细胞损伤? | Michael P.Manns 郝连杰 | 1994 | 德国医学1994，11，4： | 0 |
| 10 | Regulation of plasma erythropoietin in chronic liver disease显示文摘In a May-issue of the World Journal of Gastroenterology, there is a very interesting study by Bruno et al. on erythropoietin (EPO) levels in patients with chronic liver disease. We have very recently reported a similar, but much larger study by Tacke et al. on the role of EPO in chronic liver disease. By comparing Bruno's results with our patient cohort and applying their | Frank Tacke Tom Luedde Michael P.Manns Christian Trautwein | 2004 | World Journal of Gastroenterology2004，10，19： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员